Major Milestone Integrating Temas' proprietary RCL Platform Technology Processing with 100%-Owned Critical Minerals Asset
Highlights
Vanadium extraction testwork underway using Temas' patented Regenerative Chloride Leach ("RCL") platform, first application of RCL to La Blache vanadium mineralisation
Fusion-based re-assaying delivering 10-60% higher metal values compared to historical 4-acid digestion methods, suggesting potential upside to previously reported grades
Up to 36,614 metres of historic drill core being re-assayed, materially accelerating development timelines and reducing the need for additional drilling
748 pulps from the 2022 diamond drill program resubmitted for fusion re-assay with results pending
Vanadium RCL test results expected with 45-60 days, including recovery, purity and mass balance data
Follow on RCL testwork planned for Gallium, Scandium and Chromium expanding La Blache into a multi-critical-metal development project
Temas' patented RCL platform validated in prior pilot testing to deliver up to 65% lower processing costs and produce pure TiO2
Temas' 100% owned RCL technology platform comprises 11 granted process patents, covering the extraction of multiple metals and feedstocks, including but not limited to Refractory Gold, Titanium, Nickel Laterite, Critical Minerals and Rare Earths
Fourth Quarter Highlights
Per Class B share(3): $1.03 adjusted basic earnings up 1.0%; $0.99 basic earnings down 2.0%; currency translation positive $0.04 per share
Sales increased 3.5% on 0.6% organic growth, 0.2% acquisition growth and 2.7% positive currency translation
CCL Segment and Avery posted organic sales growth of 3.6% and 3.8%, respectively, partly offset by organic declines for Checkpoint and Innovia of 8.1% and 9.1%, respectively
Operating income(1) improved 4.8%, with a 15.0% operating margin(1) up 20 bps
2025 Highlights
Per Class B share(3): $4.64 adjusted basic earnings up 7.4%; $4.59 basic earnings down 3.0%; $0.44 revaluation gain included in 2024 basic earnings; currency translation positive $0.10 per share on an adjusted basis
Sales increased 5.8% on 2.5% organic growth, 0.7% acquisition growth and 2.6% positive currency translation
Operating income(1) improved 8.7%, with a 16.2% operating margin(1) up 40 bps
Returned $523.7 million to shareholders: $223.7 million in dividends and repurchased 3.9 million Class B shares for $300.0 million.
(This release updates the release that posted earlier on February 25, 2026 to update the sub headlines.)
NDA for rusfertide submitted to the US Food and Drug Administration (FDA), with potential approval and launch this year
Company expects to opt-out of the 50:50 profit and loss sharing arrangement for rusfertide with Takeda during a 90-day window expected to open in Q2
U.S. regulatory decision for ICOTYDETM (icotrokinra) anticipated in 2026 with potential launch this year
PN-881 Phase 1 completion expected by mid-2026
Pre-clinical pipeline expanded with novel wholly-owned candidates PN-477, an oral and s.c. triple GLP-GIP-GCG agonist and PN-458, an oral and s.c. dual GLP-GIP agonist, and PN-8047, an oral hepcidin functional mimetic
Cash, cash equivalents and marketable securities of $646 million as of December 31, 2025, anticipated to provide cash runway through at least end of 2028
Read More
NDA for rusfertide submitted to the US Food and Drug Administration (FDA), with potential approval and launch this year
Company expects to opt-out of the 50:50 profit and loss sharing arrangement for rusfertide with Takeda during a 90-day window expected to open in Q2
U.S. regulatory decision for ICOTYDETM (icotrokinra) anticipated in 2026 with
potential launch this year
PN-881 Phase 1 completion expected by mid-2026
Read More
The National Children's Cancer Society (NCCS) is proud to announce it has earned the Platinum Seal of Transparency from Candid, the highest level of recognition awarded to nonprofit organizations for openness and accountability.
Read More
Sony IMX900 Pregius S Industrial Global Shutter UVC Camera | Ultra Fast 20Gbps USB 3.2 Gen 2x2 | Quad HDR and Quad Shutter Control | Excellent NIR Sensitivity at 850nm and 940nm
Read More
Backed by Spark Capital, Kleiner Perkins, and Cyberstarts, Gambit Security is the first AI-native resilience platform trusted by enterprises to deliver verifiable, continuous resilience, exposing hidden risks before they become catastrophic downtime. Through recent research, Gambit uncovered how a single AI-directed attacker compromised nine Mexican government institutions and exposed 195 million identities.
Read More
Navigating Contrasting Messaging by legacy media from Disney (DIS), Paramount Global (PARA), Comcast (CMCSA), Warner Bros. Discovery (WBD), and Newsmax (NMAX), Sinclair (SBGI), and Fox Corp. (FOX), Patriot.TV Provides Accurate Narrative regarding Elections.
Read More
BUZZ BOMB™ captures over 400,000 views and a spike in online revenue driven by strategic brand expansion and Ashley Paulson's historic record at the Jackpot Ultra Running Festival.
Read MoreCeramics and High-Temperature Processing Expert Dr. William M. Carty, Ph.D., Engaged to Lead Ferroboron Trial
Targets Supplying Magnet-Grade Ferroboron to Potential Customers for Initial Qualification in First Half of 2026
Read MoreThis press release is issued pursuant to Multilateral Instrument 62-104 - Take-Over Bids and Issuer Bids and National Instrument 62-103 - The Early Warning System and Related Take-Over Bid and Insider Reporting Issuers ("NI 62-103").
Read More